P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
Pier Luigi Zinzani,Robert T. Chen,Philippe Armand,Nathalie A. Johnson,Pauline Brice,John Radford,Vincent Ribrag,Daniel Molin,Theodoros P. Vassilakopoulos,Akihiro Tomita,Bastian von Tresckow,Margaret A. Shipp,Jianxin Lin,Akash Nahar,Arun Balakumaran,Craig H. Moskowitz +15 more
TL;DR: Patients with classical Hodgkin lymphoma (cHL) typically receive first-line chemotherapy or chemoradiotherapy, and cure rates are high, but some patients may have primary refractory cHL, c...
Journal ArticleDOI
Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
Sylvain Garciaz,Mickael Loschi,Adèle de Masson,Lucie Biard,Mélanie Mercier,Cécile Tomowiak,Jeremy Delage,Hélène Labussière-Wallet,David Sibon,Ophélie Cassuto,Cécile Borel,Jérôme Cornillon,Stanislas Nimubona,Amandine Charbonnier,Pauline Brice,Gérard Socié,Reda Bouabdallah,Régis Peffault de Latour,Flore Sicre de Fontbrune +18 more
TL;DR: Hematology and stem-cell transplantation unit, Hôpital Saint-Louis, Universit e Paris Diderot, Paris, France.
Journal ArticleDOI
Prognostic factors in advanced Hodgkin's disease--can they guide therapeutic decisions?
TL;DR: After treatment with a combination of chemotherapy and radiotherapy, patients with stage IIIA disease (no systemic symptoms, which include fever, night sweats, and weight .
Journal ArticleDOI
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study
Bénédicte Deau,Sandy Amorim,Aurore Perrot,Philippe Quittet,Jérôme Cornillon,Driss Chaoui,Jean Pierre Marolleau,Lucie Oberic,Katell Le Du,Luc-Matthieu Fornecker,Olivier Tournilhac,Anne Sophie Veillard,Isabelle Chaillol,Marie Robin,Jerome Tamburini,Pauline Brice +15 more
TL;DR: It is suggested that tandem SCT is efficient in high‐risk relapsed/refractory HL patients, although transplant‐related mortality remains high, and should be balanced with the efficacy of Brentuximab vedotin‐based post‐transplant consolidative strategies.
Journal ArticleDOI
Platelet infusion-related echocardiographic contrast.
TL;DR: Spontaneous contrast of the cardiac chambers has been reported in patients with poor left ventricular function and platelet aggregation, rather than red cell aggregation, could be involved in this echocardiographic abnormality.